Clinical trial
Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease.
NCT00301574 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease.
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2001
- Completion date
- February 29, 2004
- Enrollment
- 398 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.